within Pharmacolibrary.Drugs.ATC.D;

model D07AC11
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.03,
    Cl             = 15 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 2.5 / 1000000,
    adminCount     = 1,
    Vd             = 0.001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Amcinonide is a potent synthetic topical corticosteroid used for its anti-inflammatory and antipruritic effects in the treatment of various skin disorders such as eczema, dermatitis, and psoriasis. It is generally available as a cream, lotion, or ointment and is approved for clinical use in dermatology.</p><h4>Pharmacokinetics</h4><p>No published human pharmacokinetic studies of amcinonide with detailed PK parameters (e.g., volume of distribution, clearance, bioavailability) were identified. The following are theoretical estimates based on pharmacokinetic knowledge of medium to high potency topical corticosteroids and the general behavior of similar compounds in dermal use.</p><h4>References</h4><ol><li><p>Stoughton, RB (1982). Enhanced percutaneous penetration with 1-dodecylazacycloheptan-2-one. <i>Archives of dermatology</i> 118(7) 474–477. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/7092271/&quot;>https://pubmed.ncbi.nlm.nih.gov/7092271</a></p></li><li><p>Meynadier, J, et al., &amp; Peyron, JL (1981). [Percutaneous absorption of triamcinolone 16 alpha, 17 alpha cyclopentylene-dioxy-21-acetate (author&#x27;s transl)]. <i>Dermatologica</i> 162(5) 336–341. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/7250468/&quot;>https://pubmed.ncbi.nlm.nih.gov/7250468</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end D07AC11;
